| Serial Number | 79370605 |
| Word Mark | QUADRATEK |
| Filing Date | Thursday, March 2, 2023 |
| Status | 700 - REGISTERED |
| Status Date | Tuesday, July 2, 2024 |
| Registration Number | 7431124 |
| Registration Date | Tuesday, July 2, 2024 |
| Mark Drawing | 4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form |
| Published for Opposition Date | Tuesday, April 16, 2024 |
| Goods and Services | Medicines for the treatment and control of inflammation and immune system related diseases; pharmaceutical preparations for inflammation and immune system related diseases; chemical preparations for pharmaceutical or medical purposes, namely, for inflammation and immune system related diseases; biological preparations for the treatment and control of inflammation and immune system related diseases; allergy relief medication; allergy medication |
| Goods and Services | Biotechnology research; biomedical research services; pharmaceutical research services; scientific research and development; research and development of new products for others; scientific laboratory services; quality control for others; quality evaluation services for the medical and anesthesia industries; scientific research and development in the field of immunity and antibody screening; research and development services in the field of antibodies |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, June 1, 2023 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, June 1, 2023 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | Inmagene Biopharmaceuticals (Hangzhou) Co., Ltd. |
| Party Type | 30 - Original Registrant |
| Legal Entity Type | 99 - Other |
| Address | CN |
| Party Name | Inmagene Biopharmaceuticals (Hangzhou) Co., Ltd. |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 99 - Other |
| Address | CN |
| Party Name | Inmagene Biopharmaceuticals (Hangzhou) Co., Ltd. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 99 - Other |
| Address | CN |
| Event Date | Event Description |
| Friday, December 1, 2023 | ASSIGNED TO EXAMINER |
| Thursday, May 25, 2023 | SN ASSIGNED FOR SECT 66A APPL FROM IB |
| Thursday, June 1, 2023 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Thursday, June 1, 2023 | LIMITATION FROM ORIGINAL APPLICATION ENTERED |
| Tuesday, June 6, 2023 | APPLICATION FILING RECEIPT MAILED |
| Friday, December 1, 2023 | NON-FINAL ACTION WRITTEN |
| Saturday, December 2, 2023 | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW |
| Friday, January 19, 2024 | REFUSAL PROCESSED BY MPU |
| Friday, January 19, 2024 | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB |
| Wednesday, February 14, 2024 | REFUSAL PROCESSED BY IB |
| Monday, March 11, 2024 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Wednesday, March 27, 2024 | NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB |
| Wednesday, March 27, 2024 | NOTICE OF PUBLICATION |
| Tuesday, April 16, 2024 | PUBLISHED FOR OPPOSITION |
| Wednesday, March 27, 2024 | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB |
| Tuesday, April 16, 2024 | NOTIFICATION PROCESSED BY IB |
| Tuesday, July 2, 2024 | REGISTERED-PRINCIPAL REGISTER |
| Wednesday, October 2, 2024 | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB |